Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAMOND trial of patiromer to enable guideline-directed RAAS inhibitor therapy in heart failure with hyperkalemia
NL-OMON55106Phase 3Completed
- Sponsor
- Relypsa, Inc.
- Start
- Jan 2020
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of patiromer in heart failure with reduced ejection fraction (HFrEF) and hyperkalemia (3 arms), sponsored by Relypsa, Inc. Started Jan 2020; status: completed.
02
Drugs
patiromer
03
Conditions
heart failure with reduced ejection fraction (HFrEF)hyperkalemia
Beyond the preview
Go deeper on NL-OMON55106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55106.